Kobayashi Pharmaceutical’s Q1 2026 recorded sales of \u00a533.6 billion (YoY +3.2%), with net profit decreasing to approximately \u00a51.0 billion. Healthcare and daily\u7528\u54c1 are showing signs of recovery, but profits have declined. Continued attention to business performance is warranted.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4967","jir_company_name":"Kobayashi Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-08","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4967-20260508-01.pdf","jir_short_summary":"Kobayashi Pharmaceutical's Q1 2026 recorded sales of \u00a533.6 billion (YoY +3.2%), with net profit decreasing to approximately \u00a51.0 billion. Healthcare and daily\u7528\u54c1 are showing signs of recovery, but profits have declined. Continued attention to business performance is warranted.","jir_summary":"### Performance Overview\nKobayashi Pharmaceutical's Q1 2026 recorded net sales of 33,665 million yen (YoY +3.2%), operating profit of 1,350 million yen (down 46.7%), and net income attributable to owners of the parent of 1,036 million yen (down 36.2%). While sales of healthcare and daily\u7528\u54c1 are recovering, profit margins have declined. Segmented results show domestic sales of 24,437 million yen (+3.8%) and international sales of 10,558 million yen (+4.6%). Despite steady sales supported by new product launches and resumed advertising, rising costs and increased selling, general and administrative expenses are impacting profit margins.\n\n### Outlook and Impact on Shareholders\nGoing forward, the company plans to continue launching new products and enhancing marketing efforts to expand sales, while cost management remains a key challenge for improving profit margins. Dividend forecasts are maintained, and shareholder returns are expected to continue. The company will monitor geopolitical risks and foreign exchange fluctuations, aiming for stable growth.","jir_financial_highlights":"Net Sales: 33,665 million yen (YoY +3.2%)\nOperating Profit: 1,350 million yen (YoY -46.7%)\nNet Income Attributable to Owners of Parent: 1,036 million yen (YoY -36.2%)","jir_category":"","jir_hashtags":"#KobayashiPharmaceutical, #IRFinancialResults, #JapanStocks","jir_key_figures":"Net Sales: \u00a533,665 million (YoY +3.2%)\nNet Income Attributable to Owners of Parent: \u00a51,036 million (YoY -36.2%)\nOperating Profit: \u00a51,350 million (YoY -46.7%)","jir_meta_title":"[Kobayashi Pharmaceutical] Q1 2026 Earnings Results | Sales of \u00a533.6 billion (+3.2%)","jir_meta_description":"Kobayashi Pharmaceutical's Q1 2026 recorded sales of \u00a533.6 billion, with net profit decreasing to approximately \u00a51.0 billion. Focus on profit improvement and growth strategies is evident in the results.","jir_og_title":"[Kobayashi Pharmaceutical] Q1 2026 Earnings Results | Sales of \u00a533.6 billion (+3.2%)","jir_og_description":"Kobayashi Pharmaceutical's Q1 2026 results show sales increase but profit decline. Attention to future growth and shareholder returns is necessary.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7982,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-45944","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n